The FDA has updated the labels for all glucagon-like peptide 1 receptor agonists (GLP-1 RAs), such as semaglutide (Ozempic, Wegovy),…
Browsing: Clinical Updates
A recent study from the University of Pennsylvania indicates that GLP-1 receptor agonists, commonly used for weight loss and diabetes…
Gastroesophageal reflux disease (GERD) affects an estimated 1.03 billion people worldwide, with prevalence ranging significantly by region. Defined as a…
In 2030, the transformative potential of weight-loss drugs, particularly GLP-1 agonists like semaglutide (Ozempic/Wegovy), could yield global health and economic…
New tools in gastrointestinal bleeding (GIB) management, including hemostatic powders, capsule endoscopy, endoscopic clips, and over-the-scope devices, offer targeted approaches…
A study from the University of Pennsylvania, presented at the 2024 Digestive Disease Week (DDW), found that GLP-1 receptor agonists…
Exact Sciences unveiled data on the Cologuard Plus™ test at the American College of Gastroenterology (ACG) 2024 Annual Meeting, showcasing…
To mark Nature Reviews Gastroenterology & Hepatology’s 20th anniversary, experts discussed the microbiome’s impact on biology, the field’s current strengths…
OpenBiome, a nonprofit supplying fecal microbiota transplantation (FMT) material, announced a voluntary suspension of its distribution this week, affecting many…
The recent multisociety clinical practice document provides guidance on the perioperative management of GLP-1 receptor agonists (GLP-1RAs), emphasizing shared decision-making…